What Neurizon does

Neurizon Therapeutics is a clinical-stage biopharmaceutical company listed on the Australian Securities Exchange (ASX:PAA, formerly Pharmaust) that develops treatments for neurodegenerative diseases, with its primary focus on Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease (MND). The company's lead asset is NUZ-001 (S-Monepantel), a novel drug candidate that has completed Phase 1 and 12-month Open Label Extension (OLE) studies in a small cohort of ALS patients in Australia, demonstrating safety and tolerability with encouraging signals across exploratory clinical measures including survival, functional decline, and respiratory outcomes. The company is now advancing NUZ-001 as Regimen I within the HEALEY ALS Platform Trial, an adaptive Phase 2/3 study led by the Healey & AMG Center for ALS at Mass General Brigham in collaboration with NEALS, with patient enrolment and first dosing underway across multiple international specialist clinical sites.

Neurizon operates a pre-commercial pharmaceutical model with no current revenue; its value is driven entirely by clinical progress toward regulatory approval and future pharmaceutical product sales. The company is headquartered in Melbourne, Australia (Suite 2, Level 11, 385 Bourke Street) with an additional presence in Denver, Colorado (Head of Manufacturing). It maintains a lean team of 1-10 employees supplemented by an experienced leadership group drawn from major pharmaceutical and biotechnology companies including Hoffmann La Roche, Shire, BTG, Biogen, AstraZeneca, GlaxoSmithKline, and MSD. The business has been funded through capital raises on the ASX, including a 2016 round, a 2013 acquisition of Pitney Pharmaceuticals, and three 2025 raises totaling approximately $21.5 million led in part by Obsidian Global Partners.

The company's strategic positioning rests on a single-asset pipeline (NUZ-001) targeting a high-unmet-need orphan indication (ALS), validated by inclusion in the prestigious HEALEY ALS Platform Trial and supported by a regulatory engagement pathway. Beyond ALS, the company signals potential expansion into other neurodegenerative diseases. Its GTM motion is enterprise-focused, targeting regulatory approval and subsequent commercial launch through traditional pharmaceutical distribution channels.

Name

Neurizon

Legal name

Neurizon Therapeutics

Website

https://pharmaust.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurizon Therapeutics is a clinical-stage biopharmaceutical company developing NUZ-001 (S-Monepantel), a novel drug candidate for ALS and other neurodegenerative diseases, currently advancing through Phase 2/3 trials in the HEALEY ALS Platform Trial.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• ALS therapeutics
• Neurodegenerative disease treatments
• Clinical-stage biopharmaceutical
• Motor neuron disease drugs
• S-Monepantel development

Headquarters

HQ city

Claremont

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: As a pre-commercial biotech company in clinical development, Neurizon currently has no revenue. The company is focused on advancing NUZ-001 (S-Monepantel) through clinical trials with the goal of regulatory approval and commercial launch for ALS treatment. Future revenue will derive from pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Neurizon Therapeutics is a clinical-stage biopharmaceutical company developing NUZ-001 (S-Monepantel), a novel drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease (MND). The company is advancing NUZ-001 as Regimen I within the HEALEY ALS Platform Trial, an adaptive Phase 2/3 study led by Mass General Brigham in collaboration with NEALS. The company also evaluates potential applications of NUZ-001 across other neurodegenerative diseases.

Product overview

Neurizon is a pharmaceutical company focused on developing a single lead drug candidate, NUZ-001 (S-Monepantel), for the treatment of neurodegenerative diseases, with an initial focus on Amyotrophic Lateral Sclerosis (ALS). The product pipeline centers on this novel compound which has progressed through preclinical studies and Phase 1 trials with open-label extension, and is now advancing into Phase 2/3 clinical evaluation via the HEALEY ALS Platform Trial.

Differentiator

Problem solved

Functional benefit

Products and services

• NUZ-001 (S-Monepantel) Lead drug candidate being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS). Completed Phase 1 and 12-month Open Label Extension (OLE) studies in a small cohort of people living with ALS in Australia, demonstrating safety and tolerability with encouraging signals across exploratory clinical measures including survival, functional decline, and respiratory outcomes. Currently being evaluated as Regimen I within the HEALEY ALS Platform Trial (adaptive Phase 2/3) across multiple specialist clinical sites internationally. Intended for patients with ALS/MND.

Quantifiable outcome

• Phase 1 and OLE studies demonstrated safety and general tolerability with no treatment-related serious adverse events reported
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Healey & AMG Center for ALS at Mass General BrighamcoreStrategic or Co-development PartnerThe Healey & AMG Center for ALS at Mass General Brigham leads the HEALEY ALS Platform Trial, an adaptive Phase 2/3 study evaluating NUZ-001 (S-Monepantel) as Regimen I. This is a major international collaboration designed to efficiently evaluate potential new treatment options for people living with ALS.
• Network for Excellence in ALS (NEALS)coreStrategic or Co-development PartnerNEALS collaborates on the HEALEY ALS Platform Trial, providing a network of specialist clinical sites for conducting the Phase 2/3 study. This partnership supports efficient evaluation of potential treatments for ALS across multiple sites.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Annexon Biosciences: Annexon develops complement pathway inhibitors for neurodegenerative and autoimmune diseases including ALS. Indirect ALS peer with comparable CNS-focused pipeline and similar clinical-stage positioning.
• Eledon Pharmaceuticals: Eledon is developing tegoprubart, an anti-CD40L antibody, with programs in ALS and other immune-mediated neurological conditions. Emerging player with overlapping neurodegenerative focus.

Direct peers

• Prilenia Therapeutics: Prilenia is developing pridopidine for ALS and Huntington's disease, with established HEALEY ALS Platform Trial participation. Direct competitor in the same clinical infrastructure and target indication.
• Cytokinetics: Cytokinetics is developing reldesemtiv and other fast skeletal muscle troponin activators for ALS and is a long-standing player in ALS clinical development. Closely matches Neurizon in target indication and clinical-stage positioning.
• Ionis Pharmaceuticals: Ionis develops antisense oligonucleotide therapies including programs targeting SOD1-ALS and other neurodegenerative diseases via the same NEALS/Healey-aligned scientific ecosystem. Highly comparable in modality focus and target population.
• AB Science: AB Science is developing masitinib for ALS in Phase 3 trials. Direct peer in late-stage ALS drug development with a similar small-molecule repositioning strategy from an established veterinary/oncology compound base.
• Clene Nanomedicine: Clene is developing CNM-Au8, a gold nanocatalyst therapy for ALS and other neurodegenerative diseases. Direct ALS competitor at a similar clinical stage with a novel mechanism of action.
• Biogen: Biogen markets Qalsody (tofersen) for SOD1-ALS and Spinraza for SMA, and runs a substantial ALS/neurodegenerative R&D pipeline. Direct competitor to Neurizon in the ALS space with established global commercial infrastructure and regulatory credibility.

Regional players

• Mayne Pharmaceuticals: Mayne is an ASX-listed Australian specialty pharmaceutical company with overlapping board-level connections (Dr. MacFarlane serves on both boards). Comparable Australian-listed small-cap pharma peer, though operating in commercial generics/specialty rather than clinical R&D.

Broad incumbents

• Denali Therapeutics: Denali Therapeutics is developing LRRK2 and other CNS-targeted therapies for neurodegenerative diseases (Parkinson's, ALS, Hunter syndrome). Broader neuroscience incumbent with overlapping neurodegenerative R&D infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/pharmaust
• LinkedInlinkedin.com/company/pharmaust-pharmaceutical

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurizon